Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 206

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study

Chen, Ying-Xuan, Gao, Qin-Yan, Zou, Tian-Hui, Wang, Bang-Mao, Liu, Si-De, Sheng, Jian-Qiu, Ren, Jian-Lin, Zou, Xiao-Ping, Liu, Zhan-Ju, Song, Yan-Yan, Xiao, Bing, Sun, Xiao-Min, Dou, Xiao-Tan, Cao, Hai-Long, Yang, Xiao-Ning, Li, Na, Kang, Qian, Zhu, Wei, Xu, Hong-Zhi, Chen, Hui-Min, Cao, Xiao-Chuang, Fang, Jing-Yuan · 2020 · The Lancet Gastroenterology & Hepatology

Abstract

BACKGROUND Chemoprevention of colorectal adenoma and colorectal cancer remains an important public health goal. The present study aimed to investigate the clinical potential and safety of berberine for prevention of colorectal adenoma recurrence. METHODS This double-blind, randomised, placebo-controlled trial was done in seven hospital centres across six provinces in China. Individuals aged 18-75 years who had at least one but no more than six histologically confirmed colorectal adenomas that had undergone complete polypectomy within the 6 months before recruitment were recruited and randomly assigned (1:1) to receive berberine (0·3 g twice daily) or placebo tablets via block randomisation (block size of six). Participants were to undergo a first follow-up colonoscopy 1 year after enrolment, and if no colorectal adenomas were detected, a second follow-up colonoscopy at 2 years was planned. The study continued until the last enrolled participant reached the 2-year follow-up point. All participants, investigators, endoscopists, and pathologists were blinded to treatment assignment. The primary efficacy endpoint was the recurrence of adenomas at any follow-up colonoscopy. Analysis was based on modified intention-to-treat, with the full analysis set including all randomised participants who received at least one dose of study medication and who had available efficacy data. The study is registered with ClinicalTrials.gov, number NCT02226185; the trial has ended and this report represents the final analysis. FINDINGS Between Nov 14, 2014, and Dec 30, 2016, 553 participants were randomly assigned to the berberine group and 555 to the placebo group. The full analysis set consisted of 429 participants in the berberine group and 462 in the placebo group. 155 (36%) participants in the berberine group and 216 (47%) in the placebo group were found to have recurrent adenoma during follow-up (unadjusted relative risk ratio for recurrence 0·77, 95% CI 0·66-0·91; p=0·001). No colorectal cancers were detected during follow-up. The most common adverse event was constipation (six [1%] of 446 patients in the berberine group vs one [<0·5%] of 478 in the placebo group). No serious adverse events were reported. INTERPRETATION Berberine 0·3 g twice daily was safe and effective in reducing the risk of recurrence of colorectal adenoma and could be an option for chemoprevention after polypectomy. FUNDING National Natural Science Foundation of China.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2468-1253(19)30409-1

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 206

Metadata

Authors
Chen, Y.-X., Gao, Q.-Y., Zou, T.-H., Wang, B.-M., Liu, S.-D., Sheng, J.-Q., Ren, J.-L., Zou, X.-P., Liu, Z.-J., Song, Y.-Y., Xiao, B., Sun, X.-M., Dou, X.-T., Cao, H.-L., Yang, X.-N., Li, N., Kang, Q., Zhu, W., Xu, H.-Z., Chen, H.-M., Cao, X.-C., & Fang, J.-Y.
Venue
The Lancet Gastroenterology & Hepatology
Publisher
Elsevier BV
Published
2020-03
Volume
5
Issue
3
Pages
267-275
ISSN
  • 2468-1156 (ISSN-L)
  • 2468-1253
OpenAlex
W2999960074
Cited by
206
References
10
FWCI
13.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. https://app.cochat.ai/papers/10.1016/s2468-1253(19)30409-1
The paper
Chen, Y.-X., Gao, Q.-Y., Zou, T.-H., Wang, B.-M., Liu, S.-D., Sheng, J.-Q., Ren, J.-L., Zou, X.-P., Liu, Z.-J., Song, Y.-Y., Xiao, B., Sun, X.-M., Dou, X.-T., Cao, H.-L., Yang, X.-N., Li, N., Kang, Q., Zhu, W., Xu, H.-Z., . . . Fang, J.-Y. (2020). Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(19)30409-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.